Compare
Altimmune, Inc. vs Neonc Technologies Holdings, Inc. vs Lyell Immunopharma, Inc. vs Lunai Bioworks Inc.
| Latest fiscal year | Altimmune, Inc. ALT | Neonc Technologies Holdings, Inc. NTHI | Lyell Immunopharma, Inc. LYEL | Lunai Bioworks Inc. LNAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $41.0K | $40.0K | $36.0K | $52.0K |
| Revenue growth (YoY) | +105.0% | -51.8% | -41.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$88.09M | -$62.15M | -$274.45M | -$3.56M |
| EPS (Diluted) | -$1.00 | -$3.20 | -$16.06 | -$1.06 |
| Operating cash flow | -$67.53M | -$20.36M | -$150.02M | -$5.29M |
| Free cash flow | -$67.55M | -$20.86M | -$150.80M | -$5.29M |
| Cash & equivalents | $43.76M | $58.7K | $60.18M | $1.71M |
| Total assets | $279.93M | $2.82M | $340.05M | $9.94M |
| Total liabilities | $55.04M | $20.33M | $91.85M | $18.97M |
| Shareholders' equity | $224.89M | -$17.51M | $248.20M | -$9.02M |
| Return on year-end equity | -39.2% | n/a | -110.6% | n/a |
| Shares outstanding | 110.88M | 21.99M | 21.25M | 4.62M |
Revenue, most recent five fiscal years
| Fiscal year | Altimmune, Inc. | Neonc Technologies Holdings, Inc. | Lyell Immunopharma, Inc. | Lunai Bioworks Inc. |
|---|---|---|---|---|
| Latest | $41.0K Ended 2025-12-31 | $40.0K Ended 2025-12-31 | $36.0K Ended 2025-12-31 | $52.0K Ended 2026-06-30 |
| 1 year earlier | $20.0K Ended 2024-12-31 | $83.0K Ended 2024-12-31 | $61.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $426.0K Ended 2023-12-31 | n/a | $130.0K Ended 2023-12-31 | n/a |
| 3 years earlier | -$68.0K Ended 2022-12-31 | n/a | $84.68M Ended 2022-12-31 | n/a |
| 4 years earlier | $4.41M Ended 2021-12-31 | n/a | $10.65M Ended 2021-12-31 | n/a |